PROTHENA CORP PUBLIC LTD CO

PRTASEC EDGAR

Pharmaceutical Preparations(L2)CIK: 1559053

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$91.4M	$53.9M	$200.6M	$853.0K	$814.0K
Research and Development Expense	$220.6M	$135.6M	$82.3M	$74.9M	$50.8M
Operating Expenses	$282.4M	$185.5M	$128.6M	$113.6M	$86.5M
Operating Income (Loss)	-$191.0M	-$131.6M	$72.0M	-$112.7M	-$85.7M
Nonoperating Income (Expense)	$30.6M	$6.0M	-$54.0K	$1.3M	$8.4M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$160.5M	-$125.6M	$71.9M	-$111.4M	-$77.3M
Income Tax Expense (Benefit)	-$13.5M	-$8.7M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$547.1M	$696.4M	$758.0M	$609.4M	$333.0M
Assets, Current	$485.4M	$639.3M	$719.1M	$584.8M	$299.3M
Cash and Cash Equivalents, at Carrying Value	$618.8M	$710.4M	$579.1M	$295.4M	$375.7M
Accounts Receivable, after Allowance for Credit Loss, Current	—	$5.2M	$0.00	—	$15.0K
Liabilities	$60.2M	$135.0M	$136.0M	$143.3M	$149.0M
Liabilities, Current	$48.5M	$56.9M	$50.1M	$33.5M	$25.8M
Accounts Payable, Current	$7.8M	$25.4M	$9.3M	$3.7M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$133.9M	-$108.8M	$92.6M	-$80.4M	-$53.0M
Net Cash Provided by (Used in) Investing Activities	-$2.8M	-$464.0K	-$575.0K	-$196.0K	-$547.0K
Net Cash Provided by (Used in) Financing Activities	$45.1M	$241.5M	$190.3M	$215.0K	$228.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)